MPS 1 Hurler Syndrome: From Screening to Gene Therapy

MPS 1 Hurler syndrome is the most severe form of mucopolysaccharidosis type I, a rare inherited condition in which the body cannot break down certain complex sugars called glycosaminoglycans (GAGs). Without treatment, these sugars pile up inside cells throughout the body, progressively damaging the brain, skeleton, heart, airways, and other organs, typically proving fatal within the first decade of life. Stem cell transplantation performed in infancy has transformed the prognosis over the past few decades, but the disease still leaves a substantial residual burden that families and clinicians manage for a lifetime.

What Goes Wrong at the Cellular Level

The root cause is a defect in the IDUA gene, which provides instructions for making an enzyme called alpha-L-iduronidase. This enzyme normally works inside lysosomes, the recycling compartments of cells, where it helps break down two specific GAGs: heparan sulfate and dermatan sulfate.¹ When a child inherits two faulty copies of IDUA (one from each parent), the enzyme is either absent or barely functional, and those GAGs accumulate rather than getting cleared.² The inheritance pattern is autosomal recessive, meaning both parents are usually healthy carriers who each harbor one working copy and one broken copy of the gene.³

The buildup of GAGs does not just passively stretch cells. It triggers a cascade of secondary damage, including chronic inflammation, disrupted cell signaling, oxidative stress, and changes to how other molecules like gangliosides are processed.⁴ Research points to the innate immune system as a major player: accumulated GAGs appear to activate immune pathways, particularly those involving Toll-like receptor 4, setting off a self-reinforcing cycle of inflammation that drives much of the tissue destruction seen in the disease.⁵ This inflammatory dimension is a relatively recent focus in MPS research, and early animal studies suggest that anti-inflammatory drugs could complement existing enzyme-based treatments.⁶

Why MPS I Is a Spectrum, and Where Hurler Falls

Not everyone with MPS I has the same experience. The clinical picture depends largely on how much residual enzyme activity a person’s particular mutations leave behind. Historically, clinicians described three syndromes along this spectrum: Hurler (severe), Hurler-Scheie (intermediate), and Scheie (attenuated). Biochemical studies have shown that patients at the attenuated end can retain up to about 7% of normal enzyme capacity, while those with the severe Hurler phenotype have less than roughly 0.1%.⁷ That tiny difference matters enormously. Children with Hurler syndrome typically show symptoms in the first year of life and, without intervention, face progressive cognitive decline, organ failure, and death before age ten. Individuals at the milder end may not be diagnosed until adolescence or adulthood and can have a near-normal lifespan with appropriate management.

Today, many clinicians prefer the simpler labels “severe MPS I” and “attenuated MPS I,” since the boundaries between the old categories are blurry and the treatment path differs sharply between the two groups. For the rest of this article, “Hurler syndrome” refers specifically to the severe end of the spectrum.

How the Disease Shows Itself

Hurler syndrome affects nearly every organ system, and its features usually become noticeable within the first six to eighteen months. Among the earliest signs are a coarsening of facial features, an enlarged head, frequent ear and respiratory infections, hernias, and a protuberant abdomen from an enlarged liver and spleen. Joint stiffness, particularly in the hands, becomes apparent early and progresses to what clinicians call dysostosis multiplex, a pattern of skeletal abnormalities that includes misshapen vertebrae, hip dysplasia, and claw-hand deformity.⁸

Cardiac involvement tends to emerge silently. Valve thickening, particularly on the left side of the heart, is common and can progress to significant dysfunction. Coronary artery changes and other vascular problems may also develop. Because children with Hurler syndrome may not complain of cardiac symptoms, echocardiographic screening is a standard part of their care.⁹

Hearing loss is another near-universal problem. It can be conductive (caused by fluid or structural changes in the middle ear), sensorineural (stemming from damage to the inner ear or auditory nerve), or a mix of both. The sensorineural component tends to worsen over time, though researchers have not fully pinned down why.¹⁰ Corneal clouding also develops, ranging from a subtle haze to opacities dense enough to impair vision substantially.

The neurological dimension sets Hurler syndrome apart from the attenuated forms of MPS I. Developmental milestones slow, then plateau, then regress. Without transplantation, most children lose previously acquired skills. Even with transplantation, there is evidence that cognitive functioning and attention can lag behind unaffected peers, and many children need special education services.¹¹

Catching It Early Through Newborn Screening

Because treatment outcomes are closely tied to how early therapy begins, there has been a major push to add MPS I to newborn screening panels. The screening typically measures alpha-L-iduronidase enzyme activity on the dried blood spot already collected from every newborn. One challenge has been false positives from so-called “pseudodeficiency,” where enzyme levels are low but the child does not actually have disease. Newer screening tools that combine enzyme activity with GAG measurements have shown strong accuracy. One such tool achieved 100% sensitivity and 100% specificity in a population of 5,000 newborns, correctly flagging all seven confirmed MPS I cases while eliminating the twelve false positives that had been generated by an older enzyme-only protocol.¹² Positive screens are followed up with genetic testing and urine GAG measurements to confirm the diagnosis and, critically, to distinguish severe from attenuated forms so the right treatment path can be chosen quickly.

Newborn screening for MPS I is now part of the recommended uniform screening panel in the United States and has been adopted in several other countries, though implementation varies. The practical consequence is that many children with Hurler syndrome are now identified in the first weeks of life rather than at six to twelve months, which translates directly into earlier treatment.

Hematopoietic Stem Cell Transplantation

For severe MPS I, transplantation of blood-forming stem cells remains the standard of care. The rationale is that donor-derived cells, once they engraft and populate the body, continuously produce functional alpha-L-iduronidase, providing a permanent internal source of the missing enzyme. Donor cells also migrate into the brain as microglia, which is why transplantation can slow or prevent cognitive decline in a way that intravenous enzyme infusions cannot, since enzyme given intravenously does not cross the blood-brain barrier in meaningful amounts.

A long-term follow-up study of 25 Hurler patients transplanted over three decades found that nearly all who survived at least one year post-transplant were still alive at the last assessment, with a median age of 21 years.¹³ That is a dramatic improvement over the natural history. Cognitive results were mixed, though: verbal comprehension and reasoning abilities were higher than working memory and processing speed, where scores clustered well below average. Transplantation in the first year of life is associated with better developmental outcomes, with earlier treatment consistently linked to higher cognitive scores.¹⁴

There is an important caveat: transplantation does not fix everything. Dysostosis multiplex, the skeletal disease that causes joint stiffness, spinal problems, and hip abnormalities, persists as a disabling feature even after successful engraftment.¹⁵ Long-term orthopedic follow-up found that bone marrow transplant does not appear to alter the natural progression of musculoskeletal disease, though there may be some benefit for upper-limb joint mobility.¹⁶ Multiple orthopedic surgeries are common during childhood and adolescence.

Enzyme Replacement Therapy and How It Fits In

Laronidase, a recombinant form of alpha-L-iduronidase, was the first enzyme replacement therapy (ERT) approved for MPS I. Given as a weekly intravenous infusion, it supplies the missing enzyme directly. Studies in children under five with the severe form showed the drug was well tolerated and provided clinical benefits like reduced liver size and improved mobility, but the same work made clear that ERT alone is not curative and cannot reverse irreversible organ damage.¹⁷ Because the enzyme does not reach the brain, ERT on its own cannot prevent cognitive decline in Hurler syndrome.

What ERT can do is serve as a bridge to transplantation. In clinical practice, many children start enzyme infusions as soon as they are diagnosed, continuing until their transplant takes place. The experience of two large centers over ten years showed that pre-transplant ERT improved the clinical condition of some patients enough to allow them to tolerate the intensive conditioning regimens needed for a successful graft. In one case, a child who had needed ventilatory support for severe upper-airway obstruction was able to come off the ventilator after starting ERT and then went on to receive a successful transplant.¹⁸

Early animal work with the canine model of Hurler syndrome previewed some of ERT’s limitations in a way that proved prescient. After three months of weekly enzyme infusions, storage was cleared from the liver, spleen, and kidneys, but the brain, heart valves, and cornea showed barely detectable enzyme levels and no improvement in storage.¹⁹ This distribution problem, where intravenous enzyme is mopped up by the liver and never reaches avascular or blood-brain-barrier-protected tissues, remains the central limitation of conventional ERT.

Gene Therapy and Next-Generation Approaches

Gene therapy aims to overcome the shortcomings of both transplantation and ERT by engineering a patient’s own stem cells to produce supranormal levels of the missing enzyme. In the most advanced clinical trial of this approach, researchers collected a patient’s own blood-forming stem cells, inserted a working copy of the IDUA gene using a viral vector, and transplanted them back after conditioning. Early results were encouraging: treated children showed stable cognitive performance, continued motor development, improved or stable brain and spinal MRI findings, reduced joint stiffness, and growth tracking normally on standard charts.²⁰ Because the corrected cells are the patient’s own, the risk of graft-versus-host disease, a significant complication of donor transplants, is eliminated.

Parallel to gene therapy, researchers are exploring small molecules that could boost the effectiveness of existing enzyme replacement. One laboratory study identified a compound that, when given together with recombinant enzyme, produced roughly a threefold increase in enzyme activity inside MPS I cells and a clear reduction in accumulated heparan sulfate compared to enzyme alone.²¹ These protein stabilizers are still at an early, cell-based stage, but they represent a different strategy: rather than replacing the enzyme entirely, they try to make the delivered enzyme last longer and work harder.

Life After Transplant and the Residual Disease Burden

Families sometimes expect transplantation to be a definitive cure, but the reality is more complicated. Physical health, measured by standardized quality-of-life tools, is significantly lower than in healthy peers. One study of transplanted Hurler patients found physical summary scores about two and a half standard deviations below normal, and global functioning scores even further below.²² The good news embedded in that same data: psychosocial health was roughly in line with healthy peers, suggesting that emotional well-being and social functioning are relatively preserved even when physical health is not.

The ongoing disease burden means that children who have been successfully transplanted still need a multidisciplinary team. Orthopedic surgeons address hip dysplasia, spinal cord compression, and carpal tunnel syndrome. Ophthalmologists monitor corneal clouding and may eventually perform corneal transplants. Audiologists fit hearing aids or cochlear implants. Cardiologists follow valve function. Physical and occupational therapists work on mobility and fine motor skills. Educational specialists tailor learning support. This web of care does not typically lessen as the child grows; many of these needs persist into adulthood.

An international comparison noted that while transplantation is readily available in the United States and European Union, it is costly. Nonetheless, the one-time expense of transplantation is actually less than the accumulated lifetime cost of weekly enzyme replacement therapy for these patients.²³ For families in countries where transplantation infrastructure is limited, access remains a serious barrier, and some children receive ERT alone by default rather than by choice.

What Caregiving Actually Looks Like

The demands on families are heavy and persistent. A U.S. survey of caregivers of post-transplant MPS I children found that about 70% of working caregivers reported a negative impact on their ability to do their jobs, and over half of all caregivers were not working at all in order to care for their child.²⁴ An Irish study offered a more nuanced picture: while overall quality of life among caregivers was relatively high and resilience scores were strong, nearly half reported being very often scared that their child’s condition would worsen or that their child would die, and found those thoughts very difficult to cope with.²⁵

That combination, resilient day-to-day functioning alongside deep and persistent fear for the future, is characteristic of families managing serious chronic childhood conditions. It also underscores why psychosocial support for the whole family, not just medical management of the child, is a meaningful component of comprehensive care.

Why Timing Changes Everything

If there is a single practical message that runs through the MPS I literature, it is that earlier treatment leads to better outcomes. Transplantation in the first year of life is associated with stronger cognitive development than transplantation later, with some evidence suggesting that even within the first year, earlier is better.²⁶ This is the core argument for newborn screening: by the time a clinician recognizes the characteristic facial features and skeletal changes of Hurler syndrome, months of irreversible damage may already have occurred. Enzyme replacement started immediately after a newborn screen result can stabilize a child’s condition during the weeks or months it takes to arrange a transplant donor and prepare the conditioning regimen.²⁷

The practical reality, though, is that not all families receive their newborn screening result in time, particularly in regions where MPS I screening has not yet been implemented. And even with prompt diagnosis, the logistics of transplantation, finding a suitable donor, coordinating conditioning, managing infections, can push treatment into the second year of life. Narrowing that gap remains one of the most actionable goals in Hurler syndrome care, and it is a reason researchers are excited about gene therapy using the patient’s own cells, which eliminates the donor-search bottleneck entirely.

Open Questions in MPS I Research

Several meaningful unknowns remain. The skeletal disease is the most stubborn: neither transplantation nor enzyme replacement significantly alters the progression of dysostosis multiplex, and the biological reasons for that are not entirely clear. GAGs clearly play a role in disrupting normal cartilage and bone development, but the storage is established very early, possibly before birth, and the avascular nature of cartilage makes it difficult for any circulating enzyme to penetrate. Whether gene therapy, which can produce supranormal enzyme levels, will do better for bones than conventional transplantation is one of the most closely watched questions in the field.²⁸

The role of inflammation is another active frontier. If GAG-driven immune activation is a major engine of tissue damage, then anti-inflammatory or immunomodulatory drugs added to enzyme-based strategies could meaningfully improve outcomes. Animal models have shown promise, but human trials are still in early stages.²⁹ And on the enzyme-stabilization front, the discovery that small molecules can boost the activity of exogenous iduronidase in cells opens the door to combination regimens, though getting from a cell-culture finding to a treatment children can receive will take years of further development.